TL;DR
This study reveals that the protein SURF4 plays a critical role in the liver's secretion of lipoproteins, specifically PCSK9 and APOB. By genetically inactivating SURF4 in mouse livers, researchers observed a dramatic drop in plasma cholesterol and triglycerides, suggesting SURF4 is a promising therapeutic target for cardiovascular diseases.
What Problem Does This Paper Address?
High levels of low-density lipoprotein (LDL) cholesterol in the blood are a major risk factor for atherosclerotic cardiovascular disease. LDL clearance from the blood is regulated by the LDL receptor (LDLR) on liver cells. A protein called PCSK9 is secreted by the liver and acts to reduce the number of LDLRs on the cell surface, thereby decreasing LDL clearance and increasing plasma cholesterol.
The researchers had previously identified SURF4 as a protein that helps PCSK9 get secreted from cells. However, its exact role in the body (in vivo) and its impact on overall cholesterol metabolism were not fully understood. This paper aims to clarify the physiological function of SURF4 in the liver, particularly its role in PCSK9 and other lipoprotein secretion, and to assess its potential as a therapeutic target for managing cholesterol levels.
Methods
The study employed several key techniques:
- Generation of Hepatic SURF4-Deficient Mice: Researchers created genetically modified mice where the Surf4 gene could be specifically deleted in liver cells using a Cre-loxP system (driven by the albumin promoter, hence Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup>). This allowed them to study the effects of SURF4 loss in a controlled, tissue-specific manner.
- Acute Inactivation of Hepatic SURF4: To confirm findings and study effects in adult animals, they used CRISPR/Cas9 technology and liver-targeted siRNA to acutely deplete SURF4 in adult mice.
- Biochemical Assays: Standard assays were used to measure plasma levels of PCSK9, cholesterol, triglycerides, and apolipoprotein B (APOB).
- Western Blotting: This technique was used to detect and quantify protein levels (PCSK9, LDLR, APOB, HSP90, GAPDH) in liver lysates.
- Lipoprotein Fractionation: Fast protein liquid chromatography (FPLC) was used to separate different types of lipoproteins (VLDL, LDL, HDL) in serum and measure their cholesterol and triglyceride content.
- Oral Fat Tolerance Test: Mice were given a labeled fat load to assess how well they absorbed and processed dietary lipids.
- Histology: Liver tissue was examined microscopically (H&E and picrosirius red staining) to check for signs of liver damage, inflammation, or fibrosis.
- RNA Sequencing (RNA-seq): This was used to analyze global gene expression changes in the liver following SURF4 deletion.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- SURF4 is Crucial for PCSK9 Secretion in vivo: The study confirms that SURF4 is not just an in-vitro helper for PCSK9 secretion but plays a vital role in the liver of living animals. Reducing SURF4 significantly lowered circulating PCSK9.
- Beyond PCSK9: A Broader Role in Lipoprotein Secretion: While the PCSK9 link was expected, the most surprising finding was the profound reduction in plasma cholesterol and triglycerides, far exceeding what would be predicted by the LDLR increase alone. This pointed to a more significant defect in the liver's ability to secrete lipoproteins, specifically APOB-containing particles.
- SURF4 as a Gatekeeper for Lipoprotein Export: The data strongly suggest SURF4 acts as a critical cargo receptor, facilitating the export of not only PCSK9 but also APOB-containing lipoproteins from the liver's endoplasmic reticulum.
- Therapeutic Potential Without Overt Liver Toxicity: The inactivation of SURF4 led to significant lipid-lowering effects without causing noticeable liver damage, steatohepatitis, or fibrosis, making it an attractive target for drug development.
Key Results
- Reduced Plasma PCSK9: Hepatic SURF4 deficiency led to a ~60% reduction in serum PCSK9 levels.
- Increased Hepatic LDLR: This reduction in PCSK9 resulted in a ~1.5-fold increase in LDLR protein abundance in the liver.
- Dramatic Cholesterol Reduction: Despite the LDLR increase, plasma cholesterol levels dropped drastically, from ~54 mg/dL to ~9.5 mg/dL in homozygous knockout mice. Triglyceride levels also showed a significant reduction.
- Severe Defect in APOB Secretion: Serum APOB levels were reduced by over 98%, and APOB was found to accumulate in the ER of SURF4-deficient livers, indicating impaired secretion.
- Normal Development and Fertility: Mice with liver-specific SURF4 deletion showed normal viability, development, and fertility.
- No Liver Pathology: Histological examination revealed no signs of steatohepatitis or fibrosis, even with significant lipid changes.
- siRNA Confirmation: Acute depletion of SURF4 using siRNA in adult mice recapitulated the hypolipidemic effects, further supporting its role and therapeutic potential.
Limitations and Future Work
- Discrepancies with Other Studies: The authors acknowledge that their findings on PCSK9 levels in Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup> mice differ from a previous report by Wang et al. They suggest potential reasons for this discrepancy, including differences in mouse genetics, husbandry, or PCSK9 quantification methods.
- Potential for Disrupting Other Cargoes: While SURF4's role in PCSK9 and APOB secretion is highlighted, it's acknowledged that SURF4 may also be involved in the secretion of other proteins. Future work should weigh the benefits of SURF4 inhibition against potential toxicity from disrupting the secretion of these other SURF4-dependent cargoes.
- Mechanism of Derl3 Upregulation: The upregulation of Derl3, an ERAD component, was observed, but its exact role in the context of SURF4 deficiency requires further investigation. The authors suggest it might be an adaptive response to protein accumulation in the ER.
- Therapeutic Strategy Refinement: While siRNA demonstrated significant lipid-lowering, further research is needed to optimize therapeutic strategies, considering the potential impact on other SURF4-dependent pathways.
The study strongly supports SURF4 as a key regulator of hepatic lipoprotein secretion and a promising therapeutic target for cardiovascular disease.
Summary updated